87544
document
Risperidone in the treatment of negative symptoms of schizophrenia : a meta-analysis . Risperidone has antiserotonergic and antidopaminergic properties that may make it more effective than conventional antipsychotic agents in the treatment of the negative symptoms of schizophrenia . Clinical trials in chronic schizophrenic patients have shown trends in favor of risperidone in the control of negative symptoms compared with haloperidol , perphenazine or zuclopenthixol , but the differences were not consistently statistically significant . A meta-analysis of the pooled results from six double-blind trials showed that risperidone at doses ranging from 4 to 8 mg/day had a significantly ( p < 0.004 ) higher negative symptom response rate , defined as the percentage of patients with a 20 % or more reduction in scores on the negative subscale of the Positive and Negative Syndrome Scale , than patients receiving active controls . The combined patient population treated with 4-8 mg/day of risperidone was 1.43 times more likely to have had a clinical response on the negative symptom subscale than the combined population treated with haloperidol , perphenazine or zuclopenthixol .
87545
Intervention_Pharmacological
Risperidone
87546
Intervention_Pharmacological
Risperidone
87547
Intervention_Pharmacological
risperidone
87548
Intervention_Pharmacological
haloperidol
87549
Intervention_Pharmacological
perphenazine
87550
Intervention_Pharmacological
zuclopenthixol
87551
Intervention_Pharmacological
risperidone
87552
Intervention_Pharmacological
risperidone
87553
Intervention_Pharmacological
haloperidol
87554
Intervention_Pharmacological
perphenazine
87555
Intervention_Pharmacological
zuclopenthixol
87556
Outcome_Mental
negative symptoms
87557
Outcome_Mental
negative symptoms
87558
Outcome_Mental
negative symptoms
87559
Outcome_Mental
negative symptom response rate
87560
Outcome_Mental
more reduction in scores on the negative subscale of the Positive and Negative Syndrome Scale
87561
Outcome_Mental
clinical response on the negative symptom subscale
87562
Participant_Condition
schizophrenia :
87563
Participant_Condition
schizophrenia .